Dynavax Technologies Corporation (LON: 0IDA)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.33B |
| Revenue (ttm) | 194.59M |
| Net Income (ttm) | 15.28M |
| Shares Out | n/a |
| EPS (ttm) | 0.11 |
| PE Ratio | 86.76 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38 |
| Average Volume | 684 |
| Open | 12.67 |
| Previous Close | 12.31 |
| Day's Range | 12.59 - 12.67 |
| 52-Week Range | 9.50 - 15.15 |
| Beta | 1.34 |
| RSI | 48.41 |
| Earnings Date | Feb 21, 2025 |
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In... [Read more]
News
Dynavax Technologies Corp (DVAX) Reports Strong 2024 Financial Performance
Dynavax Technologies Corp (DVAX) Reports Strong 2024 Financial Performance
Dynavax Technologies guides Q4 and 2024 FY topline
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 mi...
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
Dynavax Technologies: What The Stock Buyback Means. What It Doesn't
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B c...
Dynavax Announces $100 Million Accelerated Share Repurchase Program
EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
Dynavax Technologies Corporation (DVAX) Q3 2024 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q3 2024 Earnings Call Transcript
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEP...
Dynavax Announces $200 Million Share Repurchase Program
EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers' po...
Dynavax Adopts Limited-Duration Stockholder Rights Plan
EMERYVILLE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin...
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sideli...
Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spence...
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million, growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initia...
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
Dynavax to Present at Upcoming Investor Conferences
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA)...
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer -...
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - ...
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi...
Dynavax Technologies: Still A Believer
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav...